Mitochondrial CaMKII causes adverse metabolic reprogramming and dilated cardiomyopathy.
Elizabeth D LuczakYuejin WuJonathan M GrangerMei-Ling A JoinerNicholas R WilsonAshish GuptaPriya UmapathiKevin R MurphyOscar E Reyes GaidoAmin SabetEleonora CorradiniWen-Wei TsengYibin WangAlbert J R HeckAn-Chi WeiRobert G WeissMark E AndersonPublished in: Nature communications (2020)
Despite the clear association between myocardial injury, heart failure and depressed myocardial energetics, little is known about upstream signals responsible for remodeling myocardial metabolism after pathological stress. Here, we report increased mitochondrial calmodulin kinase II (CaMKII) activation and left ventricular dilation in mice one week after myocardial infarction (MI) surgery. By contrast, mice with genetic mitochondrial CaMKII inhibition are protected from left ventricular dilation and dysfunction after MI. Mice with myocardial and mitochondrial CaMKII overexpression (mtCaMKII) have severe dilated cardiomyopathy and decreased ATP that causes elevated cytoplasmic resting (diastolic) Ca2+ concentration and reduced mechanical performance. We map a metabolic pathway that rescues disease phenotypes in mtCaMKII mice, providing insights into physiological and pathological metabolic consequences of CaMKII signaling in mitochondria. Our findings suggest myocardial dilation, a disease phenotype lacking specific therapies, can be prevented by targeted replacement of mitochondrial creatine kinase or mitochondrial-targeted CaMKII inhibition.
Keyphrases
- left ventricular
- oxidative stress
- heart failure
- hypertrophic cardiomyopathy
- cardiac resynchronization therapy
- high fat diet induced
- acute myocardial infarction
- left atrial
- protein kinase
- mitral valve
- blood pressure
- randomized controlled trial
- type diabetes
- drug delivery
- cell proliferation
- gene expression
- cancer therapy
- magnetic resonance imaging
- coronary artery disease
- clinical trial
- coronary artery bypass
- early onset
- atrial fibrillation
- contrast enhanced
- acute coronary syndrome
- mouse model
- adipose tissue
- placebo controlled
- ejection fraction
- percutaneous coronary intervention